{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:17:11Z","timestamp":1793132231538,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.omtm.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T16:34:45Z","timestamp":1684427685000},"page":"30-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"30","author":[{"given":"Caroline","family":"Le Guiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Lafoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Toumaniantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumeya","family":"Adjali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Anegon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Remy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Grieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Farrokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jude","family":"Samulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.05.017_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2023.05.017_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mus.23810","article-title":"Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy","volume":"48","author":"Mendell","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2023.05.017_bib3","doi-asserted-by":"crossref","first-page":"15457","DOI":"10.1074\/jbc.R200031200","article-title":"Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function","volume":"278","author":"Michele","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.05.017_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2023.05.017_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0887-8994(95)00251-0","article-title":"Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy","volume":"14","author":"Boland","year":"1996","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtm.2023.05.017_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database","volume":"4","author":"Koeks","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2023.05.017_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1590\/0004-282x20190088","article-title":"Duchenne muscular dystrophy: an historical treatment review","volume":"77","author":"Werneck","year":"2019","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.omtm.2023.05.017_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2023.05.017_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtm.2023.05.017_bib10","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51149","article-title":"Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review","volume":"7","author":"Pascual-Morena","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtm.2023.05.017_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tcmj.2014.02.002","article-title":"Hunting for a cure: the therapeutic potential of gene therapy in Duchenne muscular dystrophy","volume":"26","author":"Hashim","year":"2014","journal-title":"Tzu Chi Med. J."},{"key":"10.1016\/j.omtm.2023.05.017_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1515\/BC.1999.078","article-title":"Adeno-associated viral vectors for gene transfer and gene therapy","volume":"380","author":"B\u00fceler","year":"1999","journal-title":"Biol. Chem."},{"key":"10.1016\/j.omtm.2023.05.017_bib13","first-page":"97","article-title":"Use of adeno-associated virus as a general transduction vector for mammalian cells","volume":"158","author":"Muzyczka","year":"1992","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.omtm.2023.05.017_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/rr6","article-title":"Size does matter: overcoming the adeno-associated virus packaging limit","volume":"1","author":"Flotte","year":"2000","journal-title":"Respir. Res."},{"key":"10.1016\/j.omtm.2023.05.017_bib15","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.omtm.2019.11.015","article-title":"Micro-dystrophin gene therapy partially enhances exercise capacity in older adult mdx Mice","volume":"17","author":"Rodgers","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.05.017_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.05.017_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/hum.2008.009","article-title":"Protein trans-splicing as a means for viral vector-mediated in\u00a0vivo gene therapy","volume":"19","author":"Li","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.05.017_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/75087","article-title":"Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization","volume":"6","author":"Sun","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.05.017_bib21","doi-asserted-by":"crossref","first-page":"13714","DOI":"10.1073\/pnas.240335297","article-title":"Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model","volume":"97","author":"Wang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.05.017_bib22","first-page":"3148","article-title":"[Introduction of rod-deleted dystrophin cDNA, delta DysM3, into mdx skeletal muscle using adenovirus vector]","volume":"55","author":"Yuasa","year":"1997","journal-title":"Nihon Rinsho."},{"key":"10.1016\/j.omtm.2023.05.017_bib23","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1074\/jbc.M110.210922","article-title":"Terminal N-linked galactose is the primary receptor for adeno-associated virus 9","volume":"286","author":"Shen","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.05.017_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib25","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1128\/JVI.07232-11","article-title":"Structural insight into the unique properties of adeno-associated virus serotype 9","volume":"86","author":"DiMattia","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.05.017_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib27","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm1439","article-title":"rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice","volume":"12","author":"Gregorevic","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.05.017_bib29","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.05.017_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of novel micro-dystrophins with enhanced functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jor.20781","article-title":"Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin\/utrophin-deficient mice","volume":"27","author":"Wang","year":"2009","journal-title":"J.\u00a0Orthop. Res."},{"key":"10.1016\/j.omtm.2023.05.017_bib32","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","article-title":"Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus","volume":"24","author":"Yue","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2023.05.017_bib33","doi-asserted-by":"crossref","first-page":"e0230083","DOI":"10.1371\/journal.pone.0230083","article-title":"Characterization of brain dystrophins absence and impact in dystrophin-deficient DMDmdx rat model","volume":"15","author":"Caudal","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.05.017_bib34","doi-asserted-by":"crossref","first-page":"e110371","DOI":"10.1371\/journal.pone.0110371","article-title":"Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy","volume":"9","author":"Larcher","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.05.017_bib35","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3389\/fimmu.2019.02131","article-title":"Immunophenotype of a rat model of Duchenne's disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment","volume":"10","author":"Ouisse","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.05.017_bib36","doi-asserted-by":"crossref","first-page":"dmm047704","DOI":"10.1242\/dmm.047704","article-title":"Cardiovascular phenotype of the DMD(mdx) rat - a suitable animal model for Duchenne muscular dystrophy","volume":"14","author":"Szab\u00f3","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2023.05.017_bib37","series-title":"Animal Models in Medicine and Biology","article-title":"Duchenne muscular dystrophy animal models","author":"Egorova","year":"2021"},{"key":"10.1016\/j.omtm.2023.05.017_bib38","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41434-021-00300-7","article-title":"Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy","volume":"29","author":"Farrokhi","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jemt.20865","article-title":"Application of WGA lectin staining for visualization of the connective tissue in skeletal muscle, bone, and ligament\/tendon studies","volume":"74","author":"Kostrominova","year":"2011","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.omtm.2023.05.017_bib40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/PHM.0000000000001500","article-title":"Natural history of serum enzyme levels in Duchenne muscular dystrophy and implications for clinical practice","volume":"99","author":"Rodr\u00edguez-Cruz","year":"2020","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.omtm.2023.05.017_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/gt.2016.75","article-title":"Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications","volume":"24","author":"Wang","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib42","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T\u00a0cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.05.017_bib43","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.05.017_bib44","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1038\/srep05635","article-title":"Generation of muscular dystrophy model rats with a CRISPR\/Cas system","volume":"4","author":"Nakamura","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2023.05.017_bib45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s12967-021-03191-9","article-title":"TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD","volume":"19","author":"Creism\u00e9as","year":"2021","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omtm.2023.05.017_bib46","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/j.nmd.2017.06.546","article-title":"Exhaustive characterization of the newly developed Duchenne muscular dystrophy rat model: a unique animal model for DMD which mimics the human disease at both the muscular and the cardiac levels","volume":"27","author":"Huchet","year":"2017","journal-title":"Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2023.05.017_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2023.05.017_bib48","series-title":"Duchenne Muscular Dystrophy","author":"Emery","year":"2003"},{"key":"10.1016\/j.omtm.2023.05.017_bib49","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/mt.2011.22","article-title":"Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer","volume":"19","author":"Pulicherla","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib50","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/hum.2008.123","article-title":"Adeno-associated virus (AAV) serotype 9 provides global\u00a0cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat","volume":"19","author":"Bish","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/hgtb.2012.105","article-title":"Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer","volume":"23","author":"Fang","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2023.05.017_bib52","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.05.017_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/hgtb.2014.128","article-title":"AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart","volume":"26","author":"Pan","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2023.05.017_bib54","series-title":"Presented at the Muscular Dytsrophy Association Clinical\u00a0& Scientific Conference, March 13-16, 2022, Nashville, TN","article-title":"One year data from ambulatory boys in a phase 1B, open-label study of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD)","author":"Butterfield","year":"2022"},{"key":"10.1016\/j.omtm.2023.05.017_bib55","series-title":"Paper Presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference","article-title":"Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: update on data from the phase 1B study","author":"Belluscio","year":"2021"},{"key":"10.1016\/j.omtm.2023.05.017_bib56","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.05.017_bib57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-1-61779-370-7_15","article-title":"Biodistribution and shedding of AAV vectors","volume":"807","author":"Le Guiner","year":"2011","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T01:36:22Z","timestamp":1714786582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":57,"alternative-id":["S2329050123000797"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.05.017","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}